Cross-over study comparing effects of treatment with an angiotensin converting enzyme inhibitor and an angiotensin II type 1 receptor antagonist on cardiovascular changes in hypertension

Journal of Hypertension

Volumn 16, Issue 4, 1998, Pages 477-486

  Gillies, Leesa K ^a   Werstiuk, Eva S ^a   Lee, Robert M K W ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Angiotensin converting enzyme inhibition; Angiotensin II; Angiotensin II type 1 receptor antagonism; Arterial structure and functioning; Hypertension; Spontaneously hypertensive rats

Indexed keywords

2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NORADRENALIN; PERINDOPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY WALL; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; HYPERTENSION; INTRAGASTRIC DRUG ADMINISTRATION; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR DENSITY; SPONTANEOUSLY HYPERTENSIVE RAT; THICKNESS;

EID: 0031967380     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816040-00009     Document Type: Article

References (44)

1. Hefti F, Fischli W, Gerold M. Cilazapril prevents hypertension in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1986; 8:641-648.
2. Adams MA, Bobik A, Komer PI. Enalapril can prevent vascular amplifier development in spontaneously hypertensive rats. Hypertension 1990; 16:252-260.
3. Lee RMKW, Wang H, Smeda JS. The effect of perindopril on hypertension and stroke prevention in experimental animals. Can J Cardiol 1994; 10:33D-36D.
4. Campbell DJ, Duncan A, Kladis A, Harrap SB. Converting enzyme inhibition and its withdrawal in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1995; 26:426-436.
5. Lee RMKW, Berecek KH, Tsoporis J, McKenzie R, Triggle CR. Prevention of hypertension and vascular changes by captopril treatment. Hypertension 1991; 17:141-150.
6. Lee RMKW, Delaney KH, Lu M. Perindopril treatment prolonged the lifespan of spontaneously hypertensive rats. J Hypertens 1995; 13:471-476.
7. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF. Nonpeptide angiotensin II receptor antagonists. Trends Pharmacol Sci 1991; 12:55-61.
8. Wexler RR, Carini DJ, Duncia JV, Johnson AL, Wells GJ, Chiu AT, et al. Rationale for the chemical development of angiotensin II receptor antagonists. Am J Hypertens 1992; 5 (12 part 2):209S-220S.
9. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47:25-49.
10. Siegl PKS, Kivlighn SD, Broten TP. Pharmacology of losartan, an angiotensin II receptor antagonist, in animal models of hypertension. J Hypertens 1995; 13 (suppl 1):S15-S21.
11. Shaw LM, George PR, Oldham A, Heagerty AM. A comparison of the effect of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism on the structural changes associated with hypertension in rat small arteries. J Hypertens 1995; 13:1135-1143.
12. Morton JJ, Beattie EC, MacPherson F. Angiotensin II receptor antagonist losartan has persistent effects on blood pressure in the young spontaneously hypertensive rat: lack of relation to vascular structure. J Vasc Res 1992; 29:264-269.
13. Gillies LK, Lee RMKW. Effects of chronic blockade of angiotensin II receptor on the maintenance of hypertension and vascular changes in spontaneously hypertensive rats. Can J Physiol Pharmacol 1996; 74:1061-1069.
14. Kivlighn SD, Gabel RA, Siegl PKS. L-158,809: antihypertensive efficacy and effects on renal function in the conscious spontaneously hypertensive rat (SHR) [abstract]. FASEB J 1991; 5:1576.
15. Smeda JS. Cerebral vascular changes associated with hemorrhagic stroke in hypertension. Can J Physiol Pharmacol 1992; 70:552-564.
16. Chiu AT, McCall DE, Price WA, Wong PC, Carini DJ, Duncia JV, et al. Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 25:711-718.
17. Wu J-N, Edwards D, Berecek KH. Changes in renal angiotensin II receptors in spontaneously hypertensive rats by early treatment with the angiotensin-converting enzyme inhibitor captopril. Hypertension 1994; 23:819-822.
18. Siegl PKS, Chang RSL, Mantlo NB, Chakravarty PK, Ondeyka DL, Greenlee WJ, et al. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist. J Pharmacol Exp Ther 1992; 262:139-144.
19. Kerth PA, Vanhoutte PM. Effects of perindoprilat on endothelium-dependent relaxations and contractions in isolated blood vessels. Am J Hypertens 1991; 4 (3 part 2):226S-234S.
20. Mombouli J-V, Illiano S, Nagao T, Scott-Burden T, Vanhoutte PM. Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyperpolarizing factors. Circ Res 1992; 71:137-144.
21. Mombouli J-V, Illiano S, Vanhoutte PM. Local production of kinins contributes to the endothelium dependent relaxations evoked by converting enzyme inhibitors in isolated arteries. In: Recent progress in kinins. Basel: Birkhauser Verlag; 1992. pp. 186-195.
22. Paula RD, Lima CV, Khosla MC, Santos RAS. Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension 1995; 26:1154-1159.
23. Kohara K, Brosnihan KB, Chappell MC, Khosla MC, Ferrario CM. Angiotensin-(1-7): a member of circulating angiotensin peptides. Hypertension 1991; 17:131-138.
24. Yamamoto K, Chapell MC, Brosnihan KB, Ferrario CM. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 1992; 19:692-696.
25. Bentre IF, Ferrario CM, Morris M, Diz DI. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol 1995; 269:H313-H319.
26. Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 1996; 27:523-528.
27. O'Sullivan JB, Harrap SB. Resetting blood pressure in spontaneously hypertensive rats: the role of bradykinin. Hypertension 1995; 25:162-165.
28. Taylor JE, Defeudis FV, Moreau JP. Bradykinin antagonists: therapeutic perspectives [review]. Drug Development Res 1989; 16:1-11.
29. Morisco C, Argenziano L, Tozzi N, Mele AF, Ricciardelli B, Condorelli G, et al. Effects of angiotensin converting enzyme inhibitors on left ventricular hypertrophy. Drugs 1993; 46 (suppl 2):88-94
30. Linz W, Wiemer G, Scholkens BA. Bradykinin prevents left ventricular hypertrophy in rats. J Hypertens 1993; 11 (suppl 5):S96-S97.
31. 2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 1992; 105:771-772.
32. Ibrahim J, Schachter M, Hughes AD, Sever PS. Role of polyamines in hypertension induced by angiotensin II. Cardiovasc Res 1995; 29:50-56.
33. Folkow B, Hallback M, Lundgren Y, Sivertsson R, Weiss L. Importance of adaptive changes in vascular design for establishment of primary hypertension, studied in man and in spontaneously hypertensive rats. Circ Res 1973; 32 (suppl 1):12-113.
34. Folkow B. 'Structural factors' in primary and secondary hypertension. Hypertension 1990; 16:89-101.
35. Ohlstein EH, Gellai M, Brooks DP, Vickery L, Jugus J, Sulpizio A, et al. The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism. J Pharmacol Exp Ther 1992; 262:595-601.
36. Schweiler JH, Kahan T, Nussberger J, Hjemdahl P. Participation of prostaglandins and bradykinin in the effects of angiotensin II and converting enzyme-inhibition on sympathetic neurotransmission in vivo. Acta Physiol Scand 1994; 152:83-91.
37. Gasc J-M, Shanmugan S, Sibony M, Corvol P. Tissue-specific expression of type 1 angiotensin II receptor subtypes: an in situ hybridization study. Hypertension 1994; 24:531-537.
38. Bouby N, Bankir L, Lorens-Cortes C. Type 1 angiotensin II receptor subtypes in kidney of normal and salt-sensitive hypertensive rats. Hypertension 1996; 27:392-398.
39. Campbell DJ, Kladis A, Duncan A-M. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension 1994; 23:439-449.
40. Burnier M, Waeber B, Brunner HR. The advantages of angiotensin II antagonism. J Hypertens 1994; 12 (suppl 2):S7-S15.
41. Hollenberg MD. Pathophysiological and therapeutic implications of receptor regulation. Trends Pharmacol Sci 1985; 8:334-336.
42. Griendling KK, Lassegue B, Alexander RW. Angiotensin receptors and their therapeutic implications. Annu Rev Pharmacol Toxicol 1996; 36:281-306.
43. Zimmerman BG, Dunham EW. Tissue renin-angiotensin system: a site of drug action? Annu Rev Pharmacol Toxicol 1997; 37:53-69.
44. Chansel D, Bizet T, Vandermeersch S, Pham P, Levy B, Ardaillou R. Differential regulation of angiotensin II and losartan binding sites in glomeruli and mesangial cells. Am J Physiol 1994; 266:F384-F393.